ECCO 2022

Is the continuation of combination therapy the key to success in CD?

Microbiota manipulation: Still a lot to learn

The potential of histology in Crohn´s disease and how AI will contribute

Combined endpoints as new therapy goals

Light at the end of the Pouchitis track

Combination trials open a new door in IBD treatment

FMT in UC - still far away from the success story

Proactive TDM

Withdrawal of infliximab or anti-metabolite therapy in CD in sustained remission

Combination of biologics - finally arrived in IBD!?

When to withdraw therapy in crohn's disease?

Will we improve the management of IBD by combining biologics?

The first combination therapy trial

Filgotinib for fistulizing disease

SPARE study in ECCO 2022

Combination with different classes of drugs in moderate to severe UC

Infliximab withdrawl leeds to a higher risk of (reversible) relapse in Crohn's disease

Ustekinumab for fistulizing disease

A new opportunity for proactive TDM disease control

Combination of biologics

FMT is not a promising option for UC patients

Is stopping of therapy an option in CD?

The interleukin-17 conundrum

Proactive TDM or SOC for monitoring infliximab treatment in immun-mediated patients?

How to deescalate treatment in CD?

Is the speedity of the steroid tapering important during initiation of infliximab?

A negative control trial for FMT in UC

Ist der Therapiestopp eine Option in CD?

Allons nous améliorer la prise en charge des MICI en combinant les traitements biologiques?

Una nuova opportunità per i TDM nel controllo proattivo di malattia

FMT ist kein vielversprechender Ansatz für UC-Patienten

Combinazione di biologici

Kombination von Biologika - endlich bei IBD angekommen!?

Wann Beendigung von Infliximab oder Immunmodulatoren bei M. Crohn?

Προληπτική μέτρηση των θεραπευτικών επιπέδων του φαρμάκου (TDM) ή κλασική παρακολούθηση της θεραπείας με infliximab σε ασθενείς με ανοσιακά νοσήματα

Du nouveau sur l’allégement thérapeutique au cours de la maladie de Crohn

Il primo trial di terapia biologica di combinazione

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την αποτελεσματικότητα της θεραπείας με infliximab

מחקר SPARE ב ECCO 2022

Das Interleukin-17 Rätsel

Un essai négatif sur la transplantation de microbiote dans la RCH

Can we translate rheumatoid arthritis to ulcerative colitis?

Inflammatory bowel disease and cancer risk

Is combination therapy safe?

Which IBD patients have a higher risk of safety concerns?

COVID-19: still a moving target!

The heart is apparently safe with continuous Ozanimod treatment

Breastmilk is tuning IBD risk

A touch of the near future in IBD treatment

Muttermilch beeinflusst das IBD-Risiko

Il cuore sembra essere apparentemente al sicuro durante il trattamento continuativo con ozanimod

Uno sguardo al prossimo futuro nel trattamento delle IBD

Efficacy update on JAKis

Vedolizumab: promising data for pouchitis and IBD in children

Mucosal healing: Will efficacy data translate into real world?

Fistulizing Crohn‘s disease - new treatment options with JAKis and IL-12/IL-23 inhibition

The race is on IL-23 – exciting data for CD and UC

Guselkumab as maintenace treatment in Crohn's Disease

Selective IL-23 blockade

New opportunity in pouchitis treatment

Anti-IL-23 - a turning point?

Great news on pouchitis treatment - vedolizumab effective

Upadacitinib - will it be the game changer in UC?

JAK inhibition

Vedolizumab is effective in chronic pouchitis after IPAA for UC

New ways of treatment

Vedolizumab in chronic pouchitis - a new chapter in therapeutic algorithms?

Upadacitinib - nowy lek, duże nadzieje

JAK-Inhibition

Anti-IL-23 - eine Zeitenwende?

Wedolizumab w pouchitis - początek nowego rozdziału w terapii?

Selektive IL-23 Blockade

Guselkumab come terapia di mantenimento

Una nuova opportunità nel trattamemto della pouchite

Nuevos caminos en el tratamiento

New therapeutic goals in UC

Patient relevant outcomes also show efficacy of upadacitinib in UC

New goals for IBD

Histological findings in mirikizumab treatment

New therapy goals: urgency and disease clearance

Natural history of anal ulcerations in pediatric-onset CD

Disease control is possible!

Urgency und Disease Clearance

Disease Control ist möglich!

Histoire naturelle de la maladie de Crohn ano-périnéale pédiatrique

Nuevas objetivos en las EII

COVID-19 in patients with IBD stratified acc. to therapy

The efficacy of COVID-19 vaccines in IBD - what's new?

Skuteczność szczepień przeciw COVID-19 w IBD - nowe dane

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי דלקתיות מרובדים לפי טיפול

Point of Care Testing / AI / Telemedicine

Ultrasound as a predictor of treatment response

Ultraschall als Prädiktor des Therapieansprechens

Digitale Tools, KI und Telemedizin

Spanish women leading contribution to ECCO 2022

ECCO guidelines on pregnancy

Las mujeres lideran la contribución española a la ECCO 2022

ECCO Richtlijnen zwangerschap